Prena.life

A blue-light-emitting sleep mask to prevent or stop preterm labor.


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9





SAVING INFANT LIVES
Prena.life:
Fast Facts

Prena is a medical device company focused on safely and effectively reducing the tragedies resulting from preterm birth and dramatically reducing healthcare costs.

 

SAVING INFANT LIVES
Preterm birth affects millions

There is currently no approved safe and effective therapy for keeping a baby in the womb for more than 1-3 days during preterm labor.

There has been no reduction in the incidence of preterm birth in more than 30 years.

SAVING INFANT LIVES
How to conquer preterm birth

FACTS AND DISCOVERIES

  • Melatonin is the hormone produced in the pineal gland that signals the body that it is time to sleep.
  • Melatonin is released at night, and melatonin secretion is governed by light.
  • Labor contractions result from the interaction of melatonin and melatonin receptors that form in the uterus immediately prior to the onset of labor.

A SIMPLE SOLUTION

  • Prena has developed a photo biomodulation approach that down regulates melatonin to prevent and stop preterm contractions.
  • Our sleep mask emits, in two cycles each night, a low-intensity cerulean blue light through the eyelids of a healthy, sleeping pregnant woman.
  • The light will not disrupt the sleep of most women but should be sufficient to prevent the onset of preterm, spontaneous contractions in most pregnant women.

SAVING INFANT LIVES
Key Features / How It Works

BLUE LIGHT SLEEP MASK
The light begins 45 minutes after the woman turns the mask on, giving her time to fall asleep. The light then slowly reaches its peak and holds for 45 minutes, and then slowly recedes to off. This cycle takes place twice each night.

SUPPRESSING THE ONSET OF PRETERM LABOR
Used at home, the mask’s blue light interrupts the body’s production of melatonin, reducing the likelihood of preterm, spontaneous contractions.

STOPPING CONTRACTIONS IN PRETERM LABOR
In a hospital setting, the mask is applied to a contracting preterm woman in a dark room and monitored for two to three hours. She may be sent home with the mask for nightly use to prevent recurrence.

SAVING INFANT LIVES
Traction & Accomplishments

PRODUCT DEVELOPMENT
Prena has produced operational prototypes and masks for human testing.

CUSTOMER ACCEPTANCE AND CLINICAL TRIALS
Small usability study demonstrated the mask is well tolerated.
Two published trials have validated the technology

  • Brigham and Women’s Hospital
  • Tallahassee Memorial Hospital

PATENTS/IP
Prena has secured three US, one Canadian and one Japanese patent

MANUFACTURING / DISTRIBUTION
We have a well qualified manufacturer secured to produce our face masks for less than $60 each.

SAVING INFANT LIVES
Meet The Team


Don Rosenkoetter
EXECUTIVE CHAIRMAN & CO-FOUNDER

  • 35+ years in senior life science leadership positions within major corporations, consulting firms, NGOs and start-ups
  • Career focus has been identifying, assessing, acquiring / licensing and commercializing technology platforms with a focus on women’s health
  • Launched 20 products in 25 geographic markets in Life Science


Stephen Puckett
SENIOR BUSINESS ADVISOR

  • 35+ years in senior leadership positions in Medical Devices, Hospitals and Medical Groups
  • Serial entrepreneur
  • Commercialized products in domestic and global healthcare markets


Justin Bushko
PRODUCT DEVELOPMENT LEAD

  • 15+ years in Medical Device Project Management positions
  • Developed products generating over $5 billion in revenue
  • Led two start-ups


Bill Loughman
CFO & DIRECTOR

  • Significant financial experience in private equity raises, an IPO and a $175 million public debt offering
  • Over 15 M&A transactions and 10 business start-ups


James Olcese Ph.D.,
SCIENTIST & CO-FOUNDER

  • Authority in circadian rhythms
  • Professor at Florida State University College Of Medicine
  • Over 110 peer reviewed articles


Douglass Tatum
DIRECTOR 

  • Serial Entrepreneur
  • Managing Director, The Co-Investment Partnership
  • Chairman, Newport LLC
  • Teaching Faculty, FSU’s Moran School of Entrepreneurship


Robert F. Casper, M.D.
CLINICAL ADVISOR

  • Professor Obstetrics & Gynecology – University of Toronto
  • Camille Dan Family Research Chair in Translational Cell Biology
  • Medical Director – Toronto Centre for Advanced Reproductive Technology
  • Over 400 peer reviewed publications


Anna David, Ph.D.
CLINICAL ADVISOR

  • Professor, Honorary Consultant and Head of Research Department of Maternal Fetal Medicine, Institute for Women’s Health, University College of London
  • Fellow of the Royal College of Royal College of Obstetricians and Gynaecologists
  • Over 400 peer reviewed publications


Michael Paidas, M.D.,
CLINICAL ADVISOR

  • Professor and Chair of Department of Obstetrics and Gynecology, University of Miami
  • Chief of Staff Jackson Memorial Hospital, Jackson Health System and University Health Tower, University of  Miami
  • Over 500 published manuscripts, abstracts, books, chapters, presentations
  • Formerly Vice Chair, Obstetrics, Yale School of Medicine

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.